ArticleJournal of immunology (Baltimore, Md. : 1950)2019
cAMP Response Element Modulator α Induces Dual Specificity Protein Phosphatase 4 to Promote Effector T Cells in Juvenile-Onset Lupus.
Article in Journal of immunology (Baltimore, Md. : 1950), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- CREM Marks TCR-Driven T-Cell Activation and Associates with Favorable Prognosis in Papillary Thyroid Carcinoma: A Single-Cell and Bulk Transcriptomic Study.International journal of molecular sciences · 2026Article
- DUSP family phosphatases in cell signaling, inflammation, and chronic diseases.Journal of biomedical science · 2026Review
- Article
- Genetic and epigenetic factors shape phenotypes and outcomes in systemic lupus erythematosus - focus on juvenile-onset systemic lupus erythematosus.Current opinion in rheumatology · 2025Review
- Neuropeptidergic Input from the Lateral Hypothalamus to the Suprachiasmatic Nucleus Alters the Circadian Period in Mice.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
- Navigating the Neuroimmunomodulation Frontier: Pioneering Approaches and Promising Horizons-A Comprehensive Review.International journal of molecular sciences · 2024Review
- CAR-engineered T cell therapy as an emerging strategy for treating autoimmune diseases.Frontiers in medicine · 2024Review
- Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders.Nature reviews. Drug discovery · 2023Review
- Decreased SUV39H1 at the promoter region leads to increased CREMα and accelerates autoimmune response in CD4Clinical epigenetics · 2022Article
- [Systemic lupus erythematosus-are children small adults?]Zeitschrift fur Rheumatologie · 2022Review
- Dual-Specificity Phosphatases and Kidney Diseases.Kidney diseases (Basel, Switzerland) · 2022Review
- A Mechanistic Insight into the Pathogenic Role of Interleukin 17A in Systemic Autoimmune Diseases.Mediators of inflammation · 2022Review
- Immune system modulation in aging: Molecular mechanisms and therapeutic targets.Frontiers in immunology · 2022Review
- Cyclic AMP Response Element Modulator-α Suppresses PD-1 Expression and Promotes Effector CD4Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Emerging roles of circular RNAs in systemic lupus erythematosus.Molecular therapy. Nucleic acids · 2021Review
- Systemic Lupus Erythematosus in Children and Young People.Current rheumatology reports · 2021Review
- MAP4K Family Kinases and DUSP Family Phosphatases in T-Cell Signaling and Systemic Lupus Erythematosus.Cells · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
Effector CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.